Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001193125-25-283441
Filing Date
2025-11-14
Accepted
2025-11-14 18:28:02
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 10377
2 EX-99.1 ck0000000000-ex99_1.pdf EX-99.1 103798
  Complete submission text file 0001193125-25-283441.txt   155318
Mailing Address 2222 PONCE DE LEON BLVD. 3RD FLOOR CORAL GABLES FL 33134
Business Address 2222 PONCE DE LEON BLVD. 3RD FLOOR CORAL GABLES FL 33134 646 876 3459
RELMADA THERAPEUTICS, INC. (Subject) CIK: 0001553643 (see all company filings)

EIN.: 455401931 | State of Incorp.: NV | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-88207 | Film No.: 251488675
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 100 CRESCENT COURT SUITE 1620 DALLAS TX 75201
Business Address 100 CRESCENT COURT SUITE 1620 DALLAS TX 75201 214-364-2883
Ikarian Capital, LLC (Filed by) CIK: 0001778253 (see all company filings)

EIN.: 473466768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G